Cargando…

Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study

OBJECTIVE: This study aimed to identify possible improvements in disease-specific health-related quality of life (HRQoL) after multiple injections of botulinum toxin A over 24 weeks in Thai cervical dystonia (CD) patients. MATERIALS AND METHODS: A 24-week prospective study comparing HRQoL of Thai CD...

Descripción completa

Detalles Bibliográficos
Autores principales: Kongsaengdao, Subsai, Maneeton, Benchalak, Maneeton, Narong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237598/
https://www.ncbi.nlm.nih.gov/pubmed/28138245
http://dx.doi.org/10.2147/NDT.S116325
_version_ 1782495558199410688
author Kongsaengdao, Subsai
Maneeton, Benchalak
Maneeton, Narong
author_facet Kongsaengdao, Subsai
Maneeton, Benchalak
Maneeton, Narong
author_sort Kongsaengdao, Subsai
collection PubMed
description OBJECTIVE: This study aimed to identify possible improvements in disease-specific health-related quality of life (HRQoL) after multiple injections of botulinum toxin A over 24 weeks in Thai cervical dystonia (CD) patients. MATERIALS AND METHODS: A 24-week prospective study comparing HRQoL of Thai CD patients before and after multiple injections of botulinum toxin A at 3-month intervals was performed. Disease-specific HRQoL was assessed by using the Cervical Dystonia Impact Profile-58 questionnaire (CDIP-58) and the Craniocervical Dystonia Questionnaire-24 (CDQ-24). General HRQoL was assessed by using the Medical Outcomes’ 36-Item Short Form Health Survey (SF-36) and the EuroQoL 5-dimension questionnaire (EQ-5D). All the assessments were performed before and after the 24-week treatment period. RESULTS: A total of 20 CD patients were enrolled in this study from April to December 2011. CDIP-58 and CDQ-24 scores, which assess disease-specific HRQoL, showed a significant improvement after 24 weeks of treatment by botulinum toxin A (P<0.001). However, EQ-5D and SF-36 scores, which assess general HRQoL, showed no significant improvement after the treatment (P>0.05). CONCLUSION: CD patients’ disease-specific HRQoL improved after being treated with multiple botulinum toxin A injections. However, general HRQoL was not improved.
format Online
Article
Text
id pubmed-5237598
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-52375982017-01-30 Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study Kongsaengdao, Subsai Maneeton, Benchalak Maneeton, Narong Neuropsychiatr Dis Treat Original Research OBJECTIVE: This study aimed to identify possible improvements in disease-specific health-related quality of life (HRQoL) after multiple injections of botulinum toxin A over 24 weeks in Thai cervical dystonia (CD) patients. MATERIALS AND METHODS: A 24-week prospective study comparing HRQoL of Thai CD patients before and after multiple injections of botulinum toxin A at 3-month intervals was performed. Disease-specific HRQoL was assessed by using the Cervical Dystonia Impact Profile-58 questionnaire (CDIP-58) and the Craniocervical Dystonia Questionnaire-24 (CDQ-24). General HRQoL was assessed by using the Medical Outcomes’ 36-Item Short Form Health Survey (SF-36) and the EuroQoL 5-dimension questionnaire (EQ-5D). All the assessments were performed before and after the 24-week treatment period. RESULTS: A total of 20 CD patients were enrolled in this study from April to December 2011. CDIP-58 and CDQ-24 scores, which assess disease-specific HRQoL, showed a significant improvement after 24 weeks of treatment by botulinum toxin A (P<0.001). However, EQ-5D and SF-36 scores, which assess general HRQoL, showed no significant improvement after the treatment (P>0.05). CONCLUSION: CD patients’ disease-specific HRQoL improved after being treated with multiple botulinum toxin A injections. However, general HRQoL was not improved. Dove Medical Press 2017-01-10 /pmc/articles/PMC5237598/ /pubmed/28138245 http://dx.doi.org/10.2147/NDT.S116325 Text en © 2017 Kongsaengdao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Kongsaengdao, Subsai
Maneeton, Benchalak
Maneeton, Narong
Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study
title Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study
title_full Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study
title_fullStr Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study
title_full_unstemmed Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study
title_short Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study
title_sort quality of life in cervical dystonia after treatment with botulinum toxin a: a 24-week prospective study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237598/
https://www.ncbi.nlm.nih.gov/pubmed/28138245
http://dx.doi.org/10.2147/NDT.S116325
work_keys_str_mv AT kongsaengdaosubsai qualityoflifeincervicaldystoniaaftertreatmentwithbotulinumtoxinaa24weekprospectivestudy
AT maneetonbenchalak qualityoflifeincervicaldystoniaaftertreatmentwithbotulinumtoxinaa24weekprospectivestudy
AT maneetonnarong qualityoflifeincervicaldystoniaaftertreatmentwithbotulinumtoxinaa24weekprospectivestudy